Evidence map›Paper›PMID 27281821›Full record

ArticleThe Journal of biological chemistry2016

RNA Exosome Complex Regulates Stability of the Hepatitis B Virus X-mRNA Transcript in a Non-stop-mediated (NSD) RNA Quality Control Mechanism.

Hussein H Aly, Junya Suzuki, Koichi Watashi, Kazuaki Chayama, Shin-Ichi Hoshino, Makoto Hijikata, Takanobu Kato, Takaji Wakita

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. The emerging role of DEAD/H-box helicases in hepatitis B virus infection.Frontiers in cellular and infection microbiology · 2022
    Review
  11. Article
  12. Review
  13. The SKI complex is a broad-spectrum, host-directed antiviral drug target for coronaviruses, influenza, and filoviruses.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Hussein H AlyFrom the Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, ahussein@nih.go.jp.
Junya SuzukiFrom the Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Koichi WatashiFrom the Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan, Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), Saitama 332-0012, Japan.
Kazuaki ChayamaDepartment of Gastroenterology and Metabolism, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
Shin-Ichi HoshinoDepartment of Biological Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya 467-8603, Japan, and.
Makoto HijikataLaboratory of Human Tumor Viruses, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan.
Takanobu KatoFrom the Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Takaji WakitaFrom the Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, wakita@nih.go.jp.
National Institute of Infectious Diseases · JPHiroshima University · JPKyoto University · JPNagoya City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus (HBV) is a stealth virus, minimally inducing the interferon system required for efficient induction of both innate and adaptive immune responses. However, 90% of acutely infected adults can clear the virus, suggesting the presence of other, interferon-independent pathways leading to viral clearance. Given the known ability of helicases to bind viral nucleic acids, we performed a functional screening assay to identify helicases that regulate HBV replication. We identified the superkiller viralicidic activity 2-like (SKIV2L) RNA helicase (a homolog of the Saccharomyces cerevisiae Ski2 protein) on the basis of its direct and preferential interaction with HBV X-mRNA. This interaction was essential for HBV X-mRNA degradation at the RNA exosome. The degradation of HBV X-mRNA at the RNA exosome was also mediated by HBS1L (HBS1-like translational GTPase) protein, a known component of the host RNA quality control system. We found that the redundant HBV-precore translation initiation site present at the 3'-end of HBV X-mRNA (3' precore) is translationally active. The initiation of translation from this site without a proper stop codon was identified by the non-stop-mediated RNA decay mechanism leading to its degradation. Although 3' precore is present in the five main HBV-RNA transcripts, only X-mRNA lacks the presence of an upstream start codons for large, middle, and small (L, M, and S) HBV surface proteins. These upstream codons are in-frame with 3' precore translation initiation site, blocking its translation from the other HBV-mRNA transcripts. To our knowledge, this is the first demonstration of the anti-viral function of the non-stop-mediated RNA decay mechanism.

Indexed as

RNA StabilityCodon, InitiatorDNA HelicasesExosome Multienzyme Ribonuclease ComplexHepatitis B virusHep G2 CellsHumansRNA, MessengerRNA, ViralTrans-ActivatorsViral Regulatory and Accessory ProteinsCodon, InitiatorDNA HelicasesExosome Multienzyme Ribonuclease Complexhepatitis B virus X proteinRNA, MessengerRNA, ViralSKIV2L protein, humanTrans-ActivatorsViral Regulatory and Accessory Proteinsexosome complexHBS1Lhepatitis B virus (HBV, Hep B)Non-Stop mediated RNA Decay (NSD)RNA-binding proteinRNA degradationRNA ExosomeRNA helicaseSKIV2Lvirus restriction factor

Identifiers

PMID27281821
PMCPMC4965548
OpenAlexW2409247163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.